• <strong id="msq6a"><u id="msq6a"></u></strong>
  • <strong id="msq6a"><input id="msq6a"></input></strong>
  • CHENGHUI PHARMACEUTICAL GROUP LTD !

    <
    >

    Your current location:

    >
    >
    >
    Exhibition Invitation|Shandong Chenghui Shuangda Pharmaceuticals will meet you at CPHI Japan 2025 in Tokyo, Japan.

    Exhibition Invitation|Shandong Chenghui Shuangda Pharmaceuticals will meet you at CPHI Japan 2025 in Tokyo, Japan.

    Author:Chenghui
    Release time:
    2025-03-25
    瀏覽量




      Shandong Chenghui Shuangda Pharmaceutical Co., Ltd. cordially invites you to visit

    2025 Pharmaceutical Ingredients Exhibition (CPHI Japan) in Tokyo, Japan.
    We are pleased to invite you to visit CPHI Japan 2025 at booth 6A-07

    to talk about the opportunities for co-operation and discuss the cutting-edge trends in the industry.



    Exhibition

      ?

    Time: 9-11 April 2025
     Venue: Tokyo Big Sight, Tokyo, Japan
     Scale: More than 800 exhibitors from 50 countries, expected to attract more than 30,000 professional visitors.
      Focus areas: APIs, biological reagents, natural extracts, pharmaceutical technology and regulatory developments.


      As a benchmark exhibition for the pharmaceutical industry in Asia,

    CPHI Japan brings together the world's top companies and is a core platform for

    technological innovation, market insight and supply chain cooperation.

    Japan continues to lead the pharmaceutical industry in the direction of

    innovation with its leading R&D capabilities and stringent quality standards.





    About  us



    Product

      We will bring our core products of local anaesthetics, antiviral, cardiovascular and cerebrovascular, antitumour and veterinary raw materials to show our R&D strength of high purity APIs and intermediates. (Some of our products are shown below, please contact us if you need more products)


    Product name CAS
    *Vonoprazan Fumarate 1260141-27-2
    881681-01-2
    *Letermovir 917389-32-3
    *Dapagliflozin propanediol monohydrate 960404-48-2
    *Crisaborole 906673-24-3
    Sugammadex sodium 343306-79-6
    *Apalutamide 956104-40-8
    *Baloxavir Marboxil 1985606-14-1
    *Lotilaner 1369852-71-0
    *Ruxolitinib Phosphate 941678-49-5
    *Finerenone 1050477-31-0
    *Upadacitinib 1310726-60-3
    *Ozenoxacin 245765-41-7
    *Resmetirom 920509-32-6
    *Fexuprazan HCI 1902954-87-3
    Prilocaine 721-50-6
    Lidocaine HCI 6108-05-0
    Lidocaine 137-58-6
    Ozagrel sodium 189224-26-8
    Celecoxib 169590-42-5
    Ropivacaine HCI 132112-35-7
    Tetracaine HCI 136-47-0
    Tetracaine 94-24-6
    Prilocaine HCI 1786-81-8
    Pramoxine HCI 637-58-1
    Bupivacaine HCI 73360-54-0
    Bupivacaine 2180-92-9
    Articaine HCI 23964-57-0
    Tadalafil 171596-29-5
    Lacidipine 103890-78-4
    Urapidil HCI 64887-14-5
    *Bilastin 202189-78-4
    *Fluralaner 864731-61-3
    *Afoxolaner 1093861-60-9
    *Sarolaner 1398609-39-6
    *Oclacitinib maleate 1208319-27-0


    Veterinary intermediates

    4-acetyl-2-methylbenzoic acid 55860-35-0
    2-AMino-N-(2,2,2-trifluoroethyl)acetaMide hydrochloride 1171331-39-7
    3',5'-dichloro-2,2,2-trifluoroacetophenone 130336-16-2
    4-acetyl-1-naphthoic acid 131986-05-5
    1-[3-Chloro-5-trifluoromethylphenyl]-2,2,2-trifluoroethanone 1125812-58-9
    4-(5-(3-chloro-5-(trifluoromethyl)phenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)-1-naphthoic acid 1308362-48-2
    Trans-4-aminocyclohexanecarboxylic acid hydrochloride 27960-59-4
    N-methyl-1-((1r,4r)-4-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)cyclohexyl)methanesulfonamide maleate 1640292-55-2


    Baloxavir Marboxil Intermediates

    (R)-7-(benzyloxy)- 3,4,12,12a-tetrahydro- 1H-[1,4]oxazino[3,4- c]pyrido[2,1-f][1,2,4]- triazine-6,8-dione 1985607-70-2
    3-(Benzyloxy)-4-oxo-4h-pyran-2-carboxylic acid 119736-16-2
    7,8-difluoro-6,11-dihydro-Dibenzo[b,e]thiepin-11-ol 1985607-83-7


    Vonoprazan Fumarate Intermediates

    5-(2-fluorophenyl)-1H-Pyrrole-3-carboxaldehyde 881674-56-2
    Pyridine-3-sulfonyl chloride 16133-25-8


    Edoxaban Intermediates

    (1S,4S,5S)-4-Bromo-6-oxabicyclo[3.2.1]octan-7-one 139893-81-5
    tert-Butyl [(1R,2S,5S)-2-amino-5-[(dimethylamino)carbonyl]cyclohexyl]carbamate oxalate 1210348-34-7
    tert-butyl (1R,2S,5S)-2-aMino-5-(diMethylcarbaMoyl)cyclohexylcarbaMate 365998-36-3
    2-bromo-5-methyl-6,7-dihydro-4H-[1,3]thiazolo[5,4-c]pyridine;4-methylbenzenesulfonic acid 852291-42-0

    *All our products are not offered in countries where valid patents exist. All responsibility with repect to third parties patent rights in specific countries lies exclusively with the buyers.

    *The advanced intermediates of all above APIs are available



      We are looking forward to deepening our cooperation with our global partners to mee

    t the challenges of the industry and explore the opportunities in the emerging markets.

    Welcome to visit us at booth 6A-07. Through the global stage of CPHI Japan,

    we would like to build a new future for the pharmaceutical raw material industry together with you!


    Contact Us


    Tel: +86-531-58897029/7070

      Email: market@chsdpharma.com

      Website: www.chsdpharma.com


      April 2025, Tokyo Ariake, see you there!






    END







    copyright CHENGHUI PHARMACEUTICAL GROUP LTD 魯ICP備09070256號-1

    Product Center

    Registered products              Other products              Intermediates              R&D products             

    News and information

    Company News       Trade News      

    About Us

    Production

    Global customers

    JOIN US

    Contact Us

    Sales  center 

    EXPORT  DEPT. :

    Tel:+86-531-58897029/58897070

    Email:sales@jnchsd.com   market@jnchsd.com    

    大胆00年在线视频国产_高清免费黄片欧美_一级无码最新2022_国产无在线不卡专区